A randomized double - blind placebo - controlled cross - over trial of the <font color="blue">impact_1</font> <font color="blue">on_1</font> <font color="blue">quality_4</font> <font color="blue">of_4</font> <font color="blue">life_4</font> of continuing dexamethasone beyond 24   h following adjuvant chemotherapy for breast cancer . 
<br>
<br> Uncertainty remains about the optimal anti - emetic regimen for control of delayed <font color="blue">nausea_2</font> <font color="blue">and_2</font> <font color="blue">vomiting_2</font> after adjuvant chemotherapy for breast cancer . Many patients receive dexamethasone but complain of <font color="blue">insomnia_2</font> <font color="blue">,_2</font> <font color="blue">anxiety_2</font> <font color="blue">/_2</font> <font color="blue">agitation_2</font> <font color="blue">,_2</font> <font color="blue">and_1</font> <font color="blue">indigestion_2</font> <font color="blue">._2</font> The aim was to determine if patients receiving chemotherapy for breast cancer <font color="blue">prefer_1</font> treatment with dexamethasone or placebo <font color="blue">for_1</font> <font color="blue">prophylaxis_1</font> <font color="blue">against_1</font> <font color="blue">delayed_1</font> <font color="blue">nausea_4</font> <font color="blue">and_4</font> <font color="blue">vomiting_4</font> <font color="blue">,_4</font> <font color="blue">and_1</font> <font color="blue">to_1</font> <font color="blue">compare_1</font> <font color="blue">quality_4</font> <font color="blue">of_4</font> <font color="blue">life_4</font> <font color="blue">(_4</font> <font color="blue">QOL_4</font> <font color="blue">)_4</font> <font color="blue">between_1</font> <font color="blue">the_1</font> <font color="blue">two_1</font> <font color="blue">treatments_1</font> <font color="blue">._1</font> In this randomized , double - blind , cross - over trial , we compared oral dexamethasone ( 4   mg twice daily for 2   days ) versus placebo for chemotherapy - naïve patients with breast cancer . All patients received intravenous granisetron and dexamethasone pre - chemotherapy and oral granisetron on day 2 . <font color="blue">Primary_1</font> <font color="blue">endpoints_1</font> <font color="blue">were_1</font> <font color="blue">:_1</font> <font color="blue">(_1</font> <font color="blue">i_1</font> <font color="blue">)_1</font> <font color="blue">patient_3</font> <font color="blue">preference_3</font> <font color="blue">;_3</font> <font color="blue">(_2</font> <font color="blue">ii_2</font> <font color="blue">)_2</font> <font color="blue">difference_2</font> <font color="blue">between_2</font> <font color="blue">cycles_2</font> <font color="blue">in_2</font> <font color="blue">change_2</font> <font color="blue">of_2</font> <font color="blue">QOL_4</font> <font color="blue">from_1</font> <font color="blue">days_1</font> <font color="blue">1_1</font> <font color="blue">to_1</font> <font color="blue">8_1</font> <font color="blue">._1</font> Median age of the 94 women was 51   years ( range 27 - 76 ) : 79 received fluorouracil / epirubicin / cyclophosphamide and 15 received doxorubicin / cyclophosphamide . Thirteen withdrew pre - cycle 2 with no differences between arms . Of 80 patients stating a <font color="blue">preference_1</font> <font color="blue">,_1</font> 31 <font color="blue">preferred_1</font> placebo ( 39   % , 95   % CI : 28 - 50   % ) and 37 ( 46   % , 95   % CI : 35 - 58   % ) <font color="blue">preferred_1</font> dexamethasone ; 12 had <font color="blue">no_1</font> <font color="blue">preference_1</font> <font color="blue">._1</font> There were no differences in <font color="blue">intensity_1</font> <font color="blue">of_1</font> <font color="blue">vomiting_3</font> <font color="blue">,_3</font> <font color="blue">nausea_3</font> <font color="blue">,_3</font> <font color="blue">or_2</font> <font color="blue">time_3</font> <font color="blue">to_3</font> <font color="blue">onset_3</font> <font color="blue">of_3</font> <font color="blue">vomiting_3</font> <font color="blue">._3</font> There was greater decrease in <font color="blue">global_1</font> <font color="blue">QOL_2</font> ( p   =   0.06 ) when patients received dexamethasone . <font color="blue">No_1</font> <font color="blue">other_1</font> <font color="blue">symptom_2</font> <font color="blue">/_2</font> <font color="blue">QOL_2</font> <font color="blue">domains_1</font> differed significantly . In conclusion , no significant difference was found in <font color="blue">patient_1</font> <font color="blue">preference_1</font> <font color="blue">,_1</font> <font color="blue">QOL_2</font> <font color="blue">,_2</font> or <font color="blue">symptoms_1</font> regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .